The University of Chicago Header Logo


Peter Riedell to Recurrence

This is a "connection" page, showing publications Peter Riedell has written about Recurrence.
Connection Strength

  1. Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma. Blood Adv. 2023 09 26; 7(18):5579-5585.
    View in: PubMed
    Score: 0.049
  2. Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2023 03 28; 7(6):963-970.
    View in: PubMed
    Score: 0.047
  3. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood. 2022 03 24; 139(12):1794-1806.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.